search
Back to results

Terlipressin in Septic Shock: Effects on Microcirculation

Primary Purpose

Septic Shock, Sepsis

Status
Completed
Phase
Phase 2
Locations
Italy
Study Type
Interventional
Intervention
continuous infusion of terlipressin
Arginine vasopressin
terlipressin bolus administration
Sponsored by
University of Roma La Sapienza
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Septic Shock focused on measuring terlipressin, vasopressin, sepsis, septic shock, norepinephrine

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinical diagnosis of septic shock
  • Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg)

Exclusion Criteria:

  • Pregnancy
  • Age < 18 years
  • Present or suspected acute mesenteric ischemia
  • Vasospastic diathesis (e.g. Raynaud's syndrome or related diseases)

Sites / Locations

  • Departement of Anesthesiology and Intensive Care

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

continuous terlipressin

vasopressin

terlipressin bolus dose

Arm Description

Outcomes

Primary Outcome Measures

Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI)
Oxygen transport variables

Secondary Outcome Measures

Acid-base homeostasis
Functional capillary density (mm/mm2) (FCD)
De Backer score
Perfused Vessel Density (PVD) (mm/mm2)
Proportion of Perfused vessels (%) (PPV)

Full Information

First Posted
October 14, 2009
Last Updated
February 3, 2010
Sponsor
University of Roma La Sapienza
search

1. Study Identification

Unique Protocol Identification Number
NCT00995839
Brief Title
Terlipressin in Septic Shock: Effects on Microcirculation
Official Title
Vasopressin Receptor Agonists in Septic Shock: Effects on Microcirculation
Study Type
Interventional

2. Study Status

Record Verification Date
October 2009
Overall Recruitment Status
Completed
Study Start Date
November 2008 (undefined)
Primary Completion Date
February 2010 (Actual)
Study Completion Date
February 2010 (Actual)

3. Sponsor/Collaborators

Name of the Sponsor
University of Roma La Sapienza

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
The present study was conducted as a prospective, randomized study to investigate the effects of vasopressin receptor agonists terlipressin and vasopressin on systemic hemodynamics and microcirculation in patients with catecholamine-dependent septic shock.
Detailed Description
60 septic shock patients requiring norepinephrine to maintain mean arterial pressure between 65 and 75 mmHg despite adequate volume resuscitation will be enrolled in the study. After an initial hemodynamic resuscitation aimed at achieve a mean arterial pressure between 65 and 75 mmHg and normovolemia, patients will be randomly allocated to be treated with either a) intravenous administration of terlipressin 1 µg∙kg-1∙h-1 for 6 hrs, b) intravenous administration of arginine vasopressin 0.04 UI∙min-1 for 6 hrs, c) intravenous administration of terlipressin bolus dose of 0.5 mg (each n = 20). In all groups open label norepinephrine will be additionally administered to maintain a mean arterial pressure (MAP) between 65 and 75 mmHg, if necessary. Data from right heart catheterization and sublingual microvascular network will be obtained just before randomization (baseline) and then after 6 hours in the vasopressin, terlipressin infusion and terlipressin bolus groups. The sublingual microvascular network will be studied using the sidestream dark field (SDF)imaging. The device will be applied on the lateral side of the tongue, in an area approximately 2-4 cm from the tip of the tongue. Sequences of 10 secs from eight adjacent areas will be recorded on disk using a personal computer. These sequences will be later analyzed by an investigator blinded to the patient's diagnosis and therapy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Septic Shock, Sepsis
Keywords
terlipressin, vasopressin, sepsis, septic shock, norepinephrine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigator
Allocation
Randomized
Enrollment
60 (Actual)

8. Arms, Groups, and Interventions

Arm Title
continuous terlipressin
Arm Type
Experimental
Arm Title
vasopressin
Arm Type
Experimental
Arm Title
terlipressin bolus dose
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
continuous infusion of terlipressin
Intervention Description
Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
Intervention Type
Drug
Intervention Name(s)
Arginine vasopressin
Intervention Description
Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
Intervention Type
Drug
Intervention Name(s)
terlipressin bolus administration
Intervention Description
intravenous terlipressin bolus administration at the dose of 0.5 mg
Primary Outcome Measure Information:
Title
Systemic hemodynamic and Microcirculatory flow index of small and medium vessels (MFI)
Time Frame
over a period of 6 hrs from the time of randomization
Title
Oxygen transport variables
Time Frame
over a period of 6 from the time of randomization
Secondary Outcome Measure Information:
Title
Acid-base homeostasis
Time Frame
over a period of 6 hrs from the time of randomization
Title
Functional capillary density (mm/mm2) (FCD)
Time Frame
over a period of 6 hrs from the time of randomization
Title
De Backer score
Time Frame
over a period of 6 hrs from the time of randomization
Title
Perfused Vessel Density (PVD) (mm/mm2)
Time Frame
over a period of 6 hrs from the time of randomization
Title
Proportion of Perfused vessels (%) (PPV)
Time Frame
over a period of 6 hrs from the time of randomization

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Clinical diagnosis of septic shock Vasopressor support to maintain mean arterial pressure (MAP) between 65 and 75 mmHg despite adequate volume resuscitation (pulmonary artery occlusion pressure = 13-18 mmHg and central venous pressure = 8-12 mmHg) Exclusion Criteria: Pregnancy Age < 18 years Present or suspected acute mesenteric ischemia Vasospastic diathesis (e.g. Raynaud's syndrome or related diseases)
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrea Morelli, MD
Organizational Affiliation
University of Rome "La Sapienza", Department of Anesthesiology and Intensive Care
Official's Role
Principal Investigator
Facility Information:
Facility Name
Departement of Anesthesiology and Intensive Care
City
Rome
State/Province
I
ZIP/Postal Code
00161
Country
Italy

12. IPD Sharing Statement

Citations:
PubMed Identifier
21929764
Citation
Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, Di Russo A, D'Egidio A, Landoni G, Lombrano MR, Botticelli L, Valentini A, Zangrillo A, Pietropaoli P, Westphal M. Effects of vasopressinergic receptor agonists on sublingual microcirculation in norepinephrine-dependent septic shock. Crit Care. 2011;15(5):R217. doi: 10.1186/cc10453. Epub 2011 Sep 19.
Results Reference
derived

Learn more about this trial

Terlipressin in Septic Shock: Effects on Microcirculation

We'll reach out to this number within 24 hrs